Until now, the study of the immune system has focused almost exclusively on white blood cells, and T cells in particular, as the body's major infection fighters. However, new research was published in the open access journal PLOS Biology by Dr. Anne Fletcher and Dr. Konstantin Knoblich and colleagues.
The researchers have veered away from traditional immunology by turning the spotlight on the structural cells that build and support the immune-rich environment of lymph nodes.
Fibroblastic Reticular Cells
Their research shows that the so-called Fibroblastic Reticular Cells (FRC) that form the inner structure of human tonsils and lymph nodes exert control over T cells and their response to infection.
These larger structural cells provide both structural support and guidance to immune cells while they spend time in lymph nodes, and the researchers' new work identifies four key mechanisms by which the FRCs act to dampen down T cell responses.
The four mechanisms that FRCs use include pathways involving prostaglandin E2, the adenosine 2a receptor, indoleamine-2,3-dioxygenase, and transforming growth factor beta.
The scientists were able to inhibit all four FRC mechanisms using existing drugs and found that T cell responses were heightened in the process. Once T cells are no longer suppressed by FRCs they are readily able to expand and proliferate.
Using an entirely novel approach, the researchers, in collaboration with the University of Birmingham, examined the activation of T cells within live slices of the human tonsil and found that (in the presence or absence of key molecules), the T cells demonstrated a heightened response when FRCs were inhibited.
"It's like finding out that the walls of a home control the people living in it. It is quite a surprise to most immunologists, who—understandably—have always focused on the people, or in this case, T cells," Dr. Fletcher said, who also has an honorary role at the University of Birmingham.
"This is of great significance as we are finally able to awaken the action of T cells when they are immunosuppressed in a natural setting. This is a new, clinically-relevant technique, offering a middle ground between in vitro work and human clinical trials," Dr. Knoblich said.
"It allows researchers to test the clinical relevance of their immune-targeting therapy in live human tonsil tissue, which is readily available and often discarded in surgery," Dr. Knoblich said.
These findings will help researchers understand why T cells respond differently when activated in the test-tube, compared to their response in a live human tissue, which contains a complex microenvironment and FRCs.
The work may help efforts to improve immune responses in situations where T cells do not work as well as they should, such as in the elderly, who are very susceptible to infections like influenza, and whose immune system or vaccination response may benefit from being boosted.